Drug intelligence / Profile preview

SBI-3150

Development stage: Unknown
Lead developer: Asahi Kasei Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SBI-3150 is a first-in-class monoclonal antibody targeting phospholipase D family member 4 (PLD4), a protein specifically expressed by plasmacytoid dendritic cells (pDCs) and activated B cells. By binding to PLD4, SBI-3150 inhibits the function of these immune cells, leading to immune suppression. This dual targeting of pDCs and activated B cells is designed to modulate key drivers in autoimmune diseases, potentially offering higher efficacy and fewer side effects compared to existing therapies. The drug was originally developed by SBI Biotech and is now being developed by Asahi Kasei Pharma under an exclusive worldwide license agreement for the treatment of autoimmune diseases[1][2][3][5].

Other names: AK1910AK-1910AK 1910

Targets

PLD4 (Phospholipase D4)

Beyond the preview

Go deeper on SBI-3150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBI-3150.

Explore the full profile